R/S-(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[6-bromo-1-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835403

PubChem CID: 56670226

Max Phase: Preclinical

Molecular Formula: C30H40BrN5O10

Molecular Weight: 710.58

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CCc2cc(Br)ccc2C1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI:  InChI=1S/C30H40BrN5O10/c1-13(2)23(32-15(5)37)27(42)33-19(11-21(38)39)26(41)35-24(14(3)4)29(44)36-9-8-16-10-17(31)6-7-18(16)25(36)28(43)34-20-12-22(40)46-30(20)45/h6-7,10,13-14,19-20,23-25,30,45H,8-9,11-12H2,1-5H3,(H,32,37)(H,33,42)(H,34,43)(H,35,41)(H,38,39)/t19-,20-,23-,24-,25?,30?/m0/s1

Standard InChI Key:  FUCNIZFCNQFKLX-ZOGZNBLASA-N

Molfile:  

     RDKit          2D

 46 48  0  0  0  0  0  0  0  0999 V2000
   29.5374  -11.1516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2049  -10.6640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9493   -9.8745    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.1224   -9.8757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8700  -10.6657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6325   -9.2046    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.9848  -10.9152    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.5341  -11.9786    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8311  -12.4127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1584  -13.6780    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.0110  -13.7684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7197  -13.3480    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.2944  -13.3640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0208  -14.5933    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.4405  -13.7524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1513  -13.3319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4504  -14.5773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7395  -14.9978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1711  -14.9818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.8700  -13.7364    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.1415  -12.5070    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.5767  -13.3159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2975  -13.7204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5668  -12.4910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.3073  -14.5453    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.2818  -12.0705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0038  -12.4766    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.2732  -11.2473    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.0062  -13.3000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.7270  -13.7044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4356  -13.2840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7368  -14.5293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0260  -14.9498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4513  -14.9338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4358  -12.4590    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.1834  -14.5022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8596  -13.2371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1078  -12.0236    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.9129  -14.8869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5895  -13.6299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.6111  -14.4517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.3354  -14.8428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0346  -14.4139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0109  -13.5875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2859  -13.2020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.7602  -14.8064    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  1  5  1  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
 11 12  1  0
 11 13  1  0
 11 14  2  0
 12 15  1  0
 15 16  1  0
 15 17  1  6
 17 18  1  0
 17 19  1  0
 16 20  1  0
 16 21  2  0
 20 22  1  0
 22 23  1  0
 22 24  1  1
 23 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  2  0
 23 29  1  0
 29 30  1  0
 30 31  1  0
 30 32  1  6
 32 33  1  0
 32 34  1  0
 31 10  1  0
 31 35  2  0
 10 36  1  0
 10 37  1  0
 36 39  1  0
 40 37  1  0
 37  9  1  0
  9  8  1  0
  9 38  2  0
 41 39  1  0
 40 41  2  0
 41 42  1  0
 42 43  2  0
 43 44  1  0
 44 45  2  0
 45 40  1  0
 43 46  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CASP3 Tchem Caspase-3 (3632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 710.58Molecular Weight (Monoisotopic): 709.1959AlogP: -0.11#Rotatable Bonds: 12
Polar Surface Area: 220.54Molecular Species: ACIDHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26CX Basic pKa: CX LogP: -0.03CX LogD: -3.03
Aromatic Rings: 1Heavy Atoms: 46QED Weighted: 0.16Np Likeness Score: 0.23

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C..  (2011)  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.,  19  (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors.  2006-03-09  Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.  [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors.  2011-10-01  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.  [PMID:21903398]

Source